Drug
Orelabrutinib clinical trials
Also written ICP-022.
- studies test it
- 84
- open now
- 56
- in phase 3
- 15
- first study started
- 2017
Keep track of what changes. Save the orelabrutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- ICP-022
- 14
Combined with it in one product
Studies by the year they started
84 studies that test it; most in 2021 (14)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 14 |
| 2022 | 12 |
| 2023 | 9 |
| 2024 | 13 |
| 2025 | 12 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 58
- Phase 3
- 15
- Phase 4
- 1
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 13
Who runs them
Industry 28 · Other 56
Beijing InnoCare Pharma Tech Co., Ltd. (24) · Ruijin Hospital (11) · The First Affiliated Hospital with Nanjing Medical University (6) · Peking Union Medical College Hospital (5) · Institute of Hematology & Blood Diseases Hospital, China (3) · Sun Yat-sen University (3) · The First Affiliated Hospital of Soochow University (3) · Huashan Hospital (2)
Often tested with
Tested in the same studies.
Rituximab (14) · Lenalidomide (9) · Obinutuzumab (6) · Methotrexate (5) · R-CHOP Regimen (4) · Mesutoclax (3) · Pomalidomide (3) · Pola-R-CHP Regimen (2)
Studies
Open first, then newest update. How each study uses orelabrutinib is read from its arms, and is right about nine times in ten.
Testing it · 84
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisRecruitingPhase 3Zenas BioPharma (USA), LLCNCT07299019Written as Orelabrutinib
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRecruitingPhase 3Zenas BioPharma (USA), LLCNCT07067463Written as Orelabrutinib
- Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)Not yet recruitingPhase 1Liu QingNCT07875972Written as Orelabrutinib
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT07784101Written as Orelabrutinib
- Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSLRecruitingPhase 2/3Huashan HospitalNCT07185373Written as Orelabrutinib
- Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingPhase 2Ruijin HospitalNCT07272499Written as Orelabrutinib
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingPhase 3Ruijin HospitalNCT07719855Written as Orelabrutinib
- Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07719556Written as Orelabrutinib
- Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell LymphomaNot yet recruitingPhase 2Ou Bai, MD/PHDNCT07677813Written as R-CHOP+Orelabrutinib
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07585747Written as Orelabrutinib
- Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaRecruitingPhase 2Zhejiang Cancer HospitalNCT07554898Written as Orelabrutinib
- Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)RecruitingPhase 2Sun Yat-sen UniversityNCT04989621Written as Orelabrutinib and Rituximab
- Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07499271Written as Orelabrutinib
- MZL-IPI Risk-adapted Targeted Therapy in Untreated MZLRecruitingPhase 2Ruijin HospitalNCT06793189Written as Obinutuzumab and Orelabrutinib
- Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07448324Written as Orelabrutinib
- Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07441993Written as Orelabrutinib
- PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07410520Written as Orelabrutinib
- Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of TherapyNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07400250Written as Orelabrutinib
- Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone LymphomaRecruitingPhase 4Beijing Tongren HospitalNCT07355699Written as Orelabrutinib
- Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaRecruitingNot applicablePeking University Third HospitalNCT07257510Written as Orelabrutinib
See all 84 studies that test orelabrutinib →
Given in every arm · 1 — orelabrutinib is usual care beside what is tested
As the comparator · 1 — what is tested is compared with orelabrutinib
Codes
What other systems call orelabrutinib · ClinicalTrials.gg INT002046
- MeSH (NLM) C000729508orelabrutinibOne source ClinicalTrials.gov
- UNII (FDA) WJA5UO9E10ORELABRUTINIBConfirmed FDA, Wikidata
- Wikidata Q126122244orelabrutinibConfirmed FDA, Wikidata
- NCI Thesaurus C156173OrelabrutinibOne source FDA
- DrugBank DB16272One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729508 | orelabrutinib | One source ClinicalTrials.gov |
| UNII (FDA) | WJA5UO9E10 | ORELABRUTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q126122244 | orelabrutinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C156173 | Orelabrutinib | One source FDA |
| DrugBank | DB16272 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.